NeurologyVertex
Vertex Pharmaceuticals Reports Phase 3 Results for VX-548 in Acute Pain
BMI
Biotechnology Media Insights
Editorial Team · September 18, 2023
Vertex announces Phase 3 trial results showing VX-548 selective Nav1.8 inhibitor significantly reduces acute pain following surgery.
Vertex Pharmaceuticals today announced Phase 3 trial results for VX-548 (suzetrigine) in patients with moderate-to-severe acute pain following abdominoplasty and bunionectomy surgery. The trials met their primary endpoints, demonstrating significant reductions in pain scores compared to placebo. VX-548 showed a favorable safety profile without opioid-associated side effects.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.